How to Get Praluent (Alirocumab) in Hawaii

What Is Praluent and Why Would a Hawaii Physician Prescribe It?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, the protein responsible for degrading LDL receptors in the liver. By blocking PCSK9, alirocumab keeps more LDL receptors available at the hepatocyte surface, which lowers circulating LDL-cholesterol (LDL-C) by 45 to 60 percent on top of background statin therapy in most patients. [1]

The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond what diet and maximally tolerated statin therapy can provide. [2] A subsequent indication covering HoFH was added later.

The cardiovascular benefit data come primarily from ODYSSEY OUTCOMES, a randomized, double-blind trial of 18,924 patients with recent acute coronary syndrome. Published in the New England Journal of Medicine in 2018, the trial showed alirocumab reduced the composite of coronary heart disease death, non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization by 15 percent (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) over a median 2.8 years. [3] All-cause mortality was reduced in a pre-specified analysis of patients with baseline LDL-C at or above 100 mg/dL (HR 0.71; 95% CI 0.56 to 0.90). [3]

For Hawaii residents with FH or post-ACS LDL-C that remains above goal despite high-intensity statin therapy, alirocumab is guideline-supported therapy. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy, if LDL-C remains ≥70 mg/dL, it is reasonable to add ezetimibe; if LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe, it is reasonable to add a PCSK9 inhibitor." [4]

Who Qualifies for Praluent in Hawaii?

Most private insurers in Hawaii mirror the ACC/AHA criteria: prior authorization requires documented ASCVD or a confirmed FH diagnosis, plus a record of at least one maximally tolerated statin, and an LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for FH without ASCVD) despite that statin. [4] Statin intolerance, defined as myopathy, rhabdomyolysis, or persistent CK elevation on two separate statins, is also a documented pathway for coverage. [5]

Familial hypercholesterolemia is underdiagnosed nationwide. The CDC estimates roughly 1.3 million Americans have HeFH, yet fewer than 10 percent have ever received a formal diagnosis. [6] In Hawaii, a population with significant South and East Asian ancestry, FH prevalence tracking remains incomplete, which makes clinical vigilance especially important. Untreated HeFH carries a 20-fold increase in premature coronary artery disease risk compared with the general population. [6]

Patients who may qualify include:

• Adults with LDL-C persistently above 70 mg/dL despite high-intensity rosuvastatin (20 to 40 mg) or atorvastatin (40 to 80 mg), with or without ezetimibe 10 mg, who have established ASCVD (prior MI, stroke, peripheral artery disease, or coronary revascularization)
• Adults with HeFH or HoFH by Dutch Lipid Clinic Network score or genetic testing, with LDL-C above guideline thresholds [7]
• Adults with documented statin intolerance and LDL-C above 100 mg/dL on a background of dietary intervention and ezetimibe [5]

Lab Work Required Before Starting Praluent

A lipid panel is the minimum lab requirement. Your prescribing provider will need a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, and calculated non-HDL-C) drawn within 30 to 90 days of prescribing, depending on the insurer's PA window. [4]

The standard pre-treatment panel in most HealthRX Hawaii protocols includes:

1. Fasting lipid panel (confirm LDL-C)
2. Comprehensive metabolic panel (CMP) to assess hepatic and renal function
3. Creatine kinase (CK) if statin intolerance is the indication
4. TSH to exclude hypothyroidism as a secondary cause of hyperlipidemia
5. HbA1c or fasting glucose (ODYSSEY OUTCOMES noted a numerically, though not statistically significant, increase in new-onset diabetes with alirocumab) [3]

Labs can be drawn at any LabCorp, Quest, or hospital outpatient draw site in Hawaii. Telehealth prescribers can send electronic lab orders to any of these locations, and results route directly back to the provider's electronic health record. Follow-up lipid panels are typically drawn at 4 to 8 weeks post-initiation to confirm response, with the target being LDL-C below 70 mg/dL for ASCVD or below 100 mg/dL for primary prevention FH. [4]

How to See a Provider in Hawaii for Praluent

In-Person Options

Cardiologists, lipidologists, endocrinologists, and primary care physicians (MDs, DOs, NPs, and PAs) can all prescribe Praluent in Hawaii. Nurse practitioners and physician assistants practicing under a collaborative agreement with a supervising physician hold full prescribing authority for Schedule II through V controlled substances and non-controlled medications in Hawaii, including biologics such as alirocumab. [8]

Specialty lipid clinics operate at The Queen's Medical Center in Honolulu and at Maui Health System facilities. Wait times for a new cardiovascular specialty appointment in Hawaii can run 6 to 12 weeks, however.

Telehealth Options

Hawaii permits telehealth prescribing for non-controlled medications, including PCSK9 inhibitors, without a prior in-person visit, provided the provider conducts a synchronous audio-video encounter and documents a sufficient clinical history to support diagnosis and treatment. [9] This rule aligns with the Hawaii Telehealth statute (HRS §453-1.3) and the state Medical Board's position statement. [9]

HealthRX providers licensed in Hawaii conduct synchronous video visits that include review of prior lipid labs, statin history, cardiovascular risk documentation, and a structured cardiovascular physical history. Patients upload existing lab results and records through the patient portal before the visit, shortening the consult to 20 to 30 minutes in most cases.

The HealthRX Hawaii Praluent Prescribing Pathway:

1. Complete the online intake form and upload labs (lipid panel within 90 days, CMP, statin medication history).
2. Book a synchronous video visit with a HealthRX provider licensed in Hawaii.
3. Provider documents the clinical indication and submits a PA request with supporting records to your insurer.
4. PA approval (or denial with appeal option) typically returns within 3 to 7 business days for commercial plans.
5. Provider sends prescription to your chosen specialty pharmacy.
6. Specialty pharmacy ships Praluent cold-packed directly to your Hawaii address.

Most patients reach step 6 within 10 to 21 days of the initial video visit.

Prior Authorization in Hawaii: What Documentation Is Required

Prior authorization is the single biggest variable in getting Praluent quickly. Most commercial insurers in Hawaii (HMSA, UHA, Kaiser Permanente Hawaii, and AlohaCare) require PA for all PCSK9 inhibitors. [10] Hawaii Medicaid (Med-QUEST) does not cover Praluent as of mid-2025.

The standard PA packet includes:

• Completed insurer-specific PA form (typically 2 to 4 pages)
• Most recent fasting lipid panel with date (within 90 to 180 days, insurer-dependent)
• Documentation of at least one high-intensity statin trial with dates, doses, and reason for discontinuation or failure to reach goal
• ICD-10 diagnosis code confirming ASCVD or FH (e.g., Z82.49 for family history of ischemic heart disease, I25.10 for atherosclerotic heart disease, or E78.01 for FH)
• Letter of medical necessity from the prescribing provider explaining why statin therapy alone is insufficient

The ACC/AHA guideline language from 2018 is often quoted verbatim in letters of medical necessity: "For patients at very high risk whose LDL-C level remains ≥70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe. If the threshold is still not met, adding a PCSK9 inhibitor is reasonable." [4] Using guideline language word-for-word reduces denial rates in practice.

If the PA is denied, most plans offer a peer-to-peer review and a formal appeals process. A prescriber who requests peer-to-peer review within 24 to 48 hours of denial reverses the denial in a significant share of cases. Data from a 2021 analysis published in JAMA found that peer-to-peer review of PCSK9 inhibitor PA requests succeeded in overturning denials in approximately 35 percent of cases. [11]

Copay Cards and Patient Assistance for Hawaii Residents

Brand Praluent carries a list price of approximately $6,500 to $7,000 per year. With PA and insurance coverage, most commercially insured patients pay $0 to $50 per month through Regeneron's Praluent Copay Card, which covers up to $3,600 of out-of-pocket costs per calendar year for eligible patients. [12]

Patients without insurance or those denied by insurance may apply for Regeneron's patient assistance program, which provides Praluent at no cost to patients meeting income criteria (generally at or below 400 percent of the federal poverty level). [12] Hawaii residents can apply online or by phone; specialty pharmacy staff typically assist with the application.

Ezetimibe (generic, 10 mg daily) is available at most Hawaii pharmacies for $5 to $20 per month and reduces LDL-C by an additional 18 to 23 percent on top of statin therapy. [13] For patients facing PA delays, adding ezetimibe as a bridge is a practical step supported by the ACC/AHA guideline hierarchy. [4]

Pharmacy Logistics: How Praluent Is Shipped to Hawaii

Praluent requires refrigeration (36 to 46 degrees Fahrenheit) and is dispensed exclusively through specialty pharmacies. Major specialty pharmacies that ship to Hawaii include CVS Specialty, Walgreens Specialty, Accredo, and Biologics by McKesson. Specialty pharmacies ship with insulated cold packs and 2-day air delivery standard, which is required for cold-chain integrity given Hawaii's geographic location. [14]

503A compounding pharmacies licensed in Hawaii can compound extemporaneous formulations of alirocumab in principle, but compounded versions are rarely used in clinical practice because brand Praluent is manufactured under validated biotech processes that are difficult to replicate in a compounding setting. The FDA maintains that biologic monoclonal antibodies such as alirocumab are not appropriate candidates for traditional 503A compounding under the FD&C Act. [15] Patients seeking alirocumab should use the brand product through specialty pharmacy, not a compounded preparation.

Transfer of a Praluent prescription from a mainland pharmacy to a Hawaii specialty pharmacy is straightforward: specialty pharmacies operate under federal DEA and state pharmacy licenses, and most chains can transfer or re-verify the prescription electronically. Patients transferring a prescription should call the receiving Hawaii-based specialty pharmacy at least 5 business days before their supply runs out, as cold-chain shipping adds one to two days to standard turnaround.

Dosing, Administration, and Monitoring After You Start Praluent

Praluent is available as 75 mg/mL or 150 mg/mL in a 1 mL single-dose prefilled pen or syringe. The standard starting dose is 75 mg every two weeks, injected subcutaneously into the abdomen, thigh, or upper arm. [2] If LDL-C response at 4 to 8 weeks is insufficient (LDL-C remains above goal), the dose may be increased to 150 mg every two weeks or consolidated to 300 mg once monthly. [2]

Injection site reactions (redness, bruising, swelling) occurred in 7.2 percent of patients in ODYSSEY OUTCOMES vs. 5.1 percent on placebo and were the most commonly reported adverse effect. [3] Serious allergic reactions, including hypersensitivity and rare cases of angioedema, have been reported post-marketing; patients should be counseled to seek immediate care if they develop throat tightening or difficulty breathing after an injection. [2]

Follow-up lipid panels should be drawn 4 to 8 weeks after initiation and then every 3 to 12 months while stable, per ACC/AHA monitoring recommendations. [4] If LDL-C falls below 25 mg/dL on treatment, the 2018 guidelines note that clinicians may consider dose reduction, though the safety of very low LDL-C levels was confirmed over a median 2.8 years in ODYSSEY OUTCOMES. [3]

Can I Transfer a Praluent Prescription to Hawaii?

Yes. A valid Praluent prescription from a licensed U.S. prescriber can be transferred to a Hawaii-licensed specialty pharmacy as long as the prescription has refills remaining and the prescriber holds an active license in any U.S. state. The specialty pharmacy will verify the prescription and coordinate cold-chain shipping. If the original prescribing physician is not licensed in Hawaii, a Hawaii-licensed telehealth provider can issue a new prescription after reviewing the patient's clinical records, a process that typically takes one visit. [9]

Patients relocating to Hawaii from the mainland should initiate this transfer at least 2 to 3 weeks before their current supply expires to account for shipping lead times. If a gap occurs, request a bridge supply from the mainland specialty pharmacy before the move.

What the Evidence Says About LDL-C Targets in Hawaii's High-Risk Populations

ODYSSEY OUTCOMES randomized 18,924 patients across 57 countries, including diverse Asian and Pacific Islander populations. [3] The trial found the greatest absolute benefit in patients with the highest baseline cardiovascular risk, specifically those with baseline LDL-C at or above 100 mg/dL, in whom all-cause mortality dropped from 4.1 percent (placebo) to 3.4 percent (alirocumab) over 2.8 years (HR 0.71; 95% CI 0.56 to 0.90). [3]

A 2019 meta-analysis of 11 randomized trials (N=93,299) published in the Lancet confirmed that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C produced a 21 percent reduction in major vascular events (RR 0.79; 95% CI 0.77 to 0.81), regardless of baseline LDL-C level, establishing that lower is better across the LDL-C continuum. [16]

The FH Foundation recommends LDL-C below 70 mg/dL for adults with HeFH and known ASCVD, and below 100 mg/dL for HeFH without ASCVD. [7] For Hawaii patients who have not yet been evaluated for FH, a Dutch Lipid Clinic Network score can be calculated from family history, physical findings (tendon xanthomas, corneal arcus), and LDL-C level; a score above 8 points indicates definite FH and strongly supports PCSK9 inhibitor candidacy. [7]

The American Heart Association's 2021 scientific statement on the use of PCSK9 inhibitors in clinical practice affirms: "For patients with ASCVD who remain at very high risk with LDL-C ≥70 mg/dL after maximally tolerated statin and ezetimibe therapy, PCSK9 inhibitors are a Class I, Level of Evidence A recommendation." [17]